<DOC>
	<DOCNO>NCT02338778</DOCNO>
	<brief_summary>The purpose study evaluate safeness effectiveness mix vaccine ( MV ) . Enrolled patient receive standard treatment accord National Comprehensive Cancer Network ( NCCN ) guide line without combine MV injection . The efficacy side effect compare two group .</brief_summary>
	<brief_title>Safety Efficacy Study Mix Vaccine Hepatocyte Carcinoma Patient</brief_title>
	<detailed_description>In study , evaluation general physical status , eligible patient enrol randomly assign two arm 1:1 ratio . In control arm patient receive standard therapy accord National Comprehensive Cancer Network ( NCCN ) guide line ( control group ) experimental arm , patient receive simultaneous standard therapy injection mix vaccine ( MV ) . MV inject weekly till disease progression . Blood sample obtain baseline every week MV injection assessment clinical hematology , biochemistry measurement immunology index ( include immunoglobin , interleukin interferon ) . Patients evaluate toxicity throughout study . Side effect , progression free survival , immunology index general status record .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients diagnose hepatocyte carcinoma base histology Evaluable lesion image study Without know immunodeficiency Age &gt; 18 &lt; 80 year ago Patients unable unwilling sign inform consent Any autoimmune disorder , currently treat prednisone immune suppressive medication Positive HIV and/or RPR ( rapid plasma reagin ) Female patient pregnant breast feeding Patients , base opinion pf investigator , enrol study Prior anticancer vaccine biological immunotherapy Allergic know ingredient MV compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>mix vaccine , liver neoplasms , immunotherapy</keyword>
</DOC>